The Challenge of Heart Failure: A Growing Global Health Crisis
Every year, millions of people across the globe experience the debilitating symptoms of heart failure—a chronic, progressive condition where the heart muscle simply cannot pump enough blood to meet the body’s needs. It manifests as crushing fatigue, breathlessness from simple tasks, and fluid buildup that swells the legs and lungs. For patients, this is a terrifying and life-altering diagnosis. For healthcare systems, it represents a massive and growing burden, accounting for a significant portion of hospital admissions and readmissions, costing billions in treatment, and placing an immense strain on cardiology departments. The problem is compounded by the fact that heart failure can be notoriously difficult to diagnose, especially in its early stages. The symptoms often mimic those of other conditions like aging, obesity, or chronic lung disease, leading to delays in treatment that can worsen outcomes. While there are excellent diagnostic tools available, they are not always accessible or immediately available. The most definitive test, an echocardiogram (an ultrasound of the heart), often requires weeks of waiting for an appointment and depends heavily on the skill of the technician performing it. Blood tests, such as the NT-proBNP biomarker, are helpful but can show elevated levels for reasons unrelated to heart failure, such as kidney disease or a severe lung infection. This leads to a high rate of false positives, meaning many patients might be referred for further testing based on a test result that ultimately turns out to be a false alarm, creating unnecessary anxiety and adding to the already overflowing queues of diagnostic imaging. The medical community is clearly in need of a faster, more accessible, and more reliable way to screen for heart failure at the point of care, something that can be done quickly in a doctor’s office to help guide the next steps.
A New Hope: Acarix’s CADScor System
Enter Acarix AB, a Swedish medical device company, which has been working on a device that might offer a solution. The company’s signature product, the CADScor System, is an innovative, point-of-care diagnostic aid that uses a highly sensitive acoustic sensor, a technology known as seismocardiography (SCG), to listen to the vibrations of the chest caused by each heartbeat. The device is currently cleared by the U.S. Food and Drug Administration (FDA) and CE-marked in Europe for a different but related purpose: to quickly rule out significant coronary artery disease (CAD)—the buildup of plaques that can narrow or block the heart’s arteries and lead to heart attacks. For years, the CADScor System has successfully been helping clinicians in the emergency room, cardiology clinic, or primary care office assess a patient’s risk of CAD in less than ten minutes, avoiding unnecessary and invasive procedures like cardiac catheterizations or expensive CT scans. Now, researchers are discovering that the same powerful technology that analyzes the vibrations of the heart to detect blockages might also be able to listen for the characteristic weak and inefficient pumping action of heart failure. In a new, peer-reviewed feasibility study published in the journal PLOS Digital Health, researchers from Denmark’s Aalborg University Hospital, Aarhus University Hospital, and Odense University Hospital have validated this concept, suggesting that the CADScor System could become an even more versatile tool in the fight against heart disease. This research marks a pivotal moment, potentially expanding the utility of a single device to address the two most common reasons a patient ends up in a cardiologist’s office: coronary artery disease and heart failure.
Inside the Study: How the Acoustic Technology Was Tested
The research, titled “A feasibility study evaluating seismocardiography for the detection of heart failure,” was designed to rigorously test whether acoustic signals alone could distinguish patients with heart failure from those without. The clinical team enrolled a total of 218 patients in the study. Of these, 198 were referred by their general practitioners with a suspicion of heart failure—these are exactly the kind of patients who might benefit from a quick triage tool. An additional 20 patients with a previously confirmed diagnosis of reduced ejection fraction heart failure (HFrEF), the most severe form of the condition where the heart’s pumping ability is significantly impaired, were also enrolled to ensure the study had enough data on the most serious cases. Each participant underwent the CADScor System test, which captured their unique cardiac vibration signatures using the small, accelerometer-based sensor placed on their chest. The research team then used machine learning, an artificial intelligence technique that allows computers to learn from data, to develop two sophisticated algorithms. The first, the “AnyHF-score,” was designed to be a broad screening tool, tasked with flagging the presence of any form of heart failure. The second, the “HFrEF-score,” was more specific and designed to identify the most serious forms of the disease, specifically looking for evidence of a reduced ejection fraction—a key indicator of severe heart dysfunction. These scores were then compared against the established diagnostic standards—clinical assessment, echocardiography results, and NT-proBNP blood tests—to measure their accuracy, sensitivity, and specificity. The goal was to see if this simple patch-based technology could reliably act as a credible and efficient gatekeeper to more expensive and complex cardiac testing.
Promising Results: High Accuracy and Fewer False Alarms
The results of the study, detailed in the PLOS Digital Health publication, were remarkably encouraging from a clinical perspective. The findings demonstrated that the acoustic sensing platform of the CADScor System identified heart failure with a diagnostic accuracy comparable to the leading blood test. Specifically, the “AnyHF-score” detected heart failure of any type with a 90.9% sensitivity and an 87.5% negative predictive value, meaning that it was extremely good at correctly identifying patients who truly had the condition and, just as importantly, accurately reassuring those who did not. The more targeted “HFrEF-score” performed on par with the NT-proBNP blood test in its ability to detect reduced heart function, with comparable overall diagnostic accuracy (a 92.9% vs. 94.7% area under the curve). However, the most striking and clinically significant finding was in its specificity. The SCG-based score achieved a specificity of 92%, compared to just 68.8% for the blood test. This is a huge difference on the front lines of medicine. In practical terms, this means the CADScor technology produced significantly fewer false positives. It was far less likely to mistakenly raise the alarm in a patient who did not have heart failure. This translated to a more than doubled positive predictive value (57.7% vs. 27.1%), which is the probability that a patient who screens positive actually has the disease. For the clinician, this means a much clearer and more trustworthy signal. A positive result on the CADScor is much more likely to be a real case of heart failure than a positive result on the standard blood test, which can be elevated for a host of unrelated reasons. This could save countless patients from unnecessary, invasive, and expensive follow-up tests while also relieving the immense pressure on cardiology departments and echocardiography labs.
Real-World Implications: Streamlining Care and Reducing Unnecessary Stress
Beyond the impressive analytics, the study shed light on how this technology could transform the diagnostic pathway for suspected heart failure in the real world. The study found that the SCG-based scores identified 71 out of 139 patients, a full 51% of those referred for suspected heart failure but ultimately found not to have the condition, as being at “minimal risk.” This is a profound finding. It suggests that this simple, acoustic test could be used right in the primary care physician’s office as a rule-out tool. Imagine a patient experiencing shortness of breath. Instead of automatically scheduling an echocardiogram, which might take weeks or months to obtain, the doctor could perform a 10-minute test with the CADScor System. If the result is low risk, the physician can be highly confident that heart failure is unlikely, potentially avoiding an unnecessary referral to a cardiologist and an unnecessary ultrasound scan. This not only expedites the process for patients who might have other issues but also dramatically shortens wait times for those who do need to see a specialist. It streamlines the entire care pathway, making it more efficient, cost-effective, and patient-centered. “Heart failure and coronary artery disease are the two biggest reasons patients end up in front of a cardiologist, and this new research opens up a whole new frontier for our CADScor System,” noted Aamir Mahmood, CEO of Acarix, in a statement. “We built CADScor to give clinicians a fast, accurate, first-line tool for cardiac triage, and these results show we can bring that same value to heart failure.” This dual capability would be a game-changer, providing a single, portable device that can triage two of the most common and costly cardiac conditions in the world.
Looking Ahead: Validation and Future Prospects
While the study’s authors and the company are excited about these findings, they are careful to temper the enthusiasm with scientific prudence. The researchers describe the results as “exploratory.” The study was conducted in a relatively modestly-sized population at just two centers in Denmark. To ensure the algorithms can be trusted in the diverse, messy world of real-world medicine, they will need to be externally validated in much larger, independent cohorts that represent a broader range of patients, different ethnicities, and various other comorbidities. This is a critical step before broader clinical adoption can be recommended. The heart failure algorithm in question is currently an investigational feature. Acarix has built it into the mechanics of its second-generation device, but it is not yet approved by the U.S. FDA for this specific use. The company will need to submit this new algorithm for FDA approval, a process that will undeniably require the larger validation trial to demonstrate its safety and effectiveness to the regulator’s standards. For Acarix, this exciting prospect represents a significant expansion of their business. The CADScor System, already a success with over 60,000 patient assessments for CAD, could become a two-in-one diagnostic aid to tackle the two biggest killers and hospitalizers in cardiology. The implications for healthcare systems are immense, offering a path to more sustainable and efficient cardiac diagnostics. As the company works toward this next phase of research and regulatory approval, the promise of this technology gives hope for a future where a quick, painless, and highly accurate scan can de-escalate a frightening symptom and steer patients towards the right treatment pathway faster than ever before, saving both valuable time and irreplaceable healthy heart muscle.